News|Articles|October 29, 2025

Topcon Healthcare seeks to advance company through acquisition and new investment

Listen
0:00 / 0:00

Key Takeaways

  • Topcon Healthcare's acquisition of Toku, Inc. aims to enhance predictive health insights using Toku's extensive retinal-image dataset.
  • Sanro Health's investment in Topcon focuses on aligning ophthalmic data for actionable insights, leveraging the Sanro Optimizer.
SHOW MORE

Topcon Healthcare enhances its AI capabilities by acquiring Toku, Inc., aiming to revolutionize eye care with advanced predictive health insights.

Topcon Healthcare will acquire Toku, Inc., according to a press release issued by the company. Toku is a healthcare artificial intelligence (AI) company that uses color fundus photographs to deliver assessments of health. The release notes that Toku’s planforms “are powered by one of the world’s largest retinal-image datasets.”1 Toku reports that, as of the press release, the company has analyzed over 4.3 million de-identified retinal images linked to clinical data.1

The acquisition and integration of these platforms into Topcon’s current suite of offerings have the potential to leverage “oculomics to empower both primary care and eyecare providers with predictive, preventive health insights.”1

The financial aspects of this deal were not disclosed in the press release.

In the week following the announcement of this acquisition, Sanro Health, Inc. is reported to have made an investment in Topcon Healthcare. According to the joint release issued from Topcon and Sanro Health, the goal of this investment is to allow the 2 companies to work together to align ophthalmic data to be useable and actionable.2

Notably, the Sanro Optimizer is a program that “integrates electronic health record and imaging data to create intelligent patient profiles and ranked cohorts, identifying eligible participants for clinical trials in real time during routine patient care across eyecare providers. This capability establishes a foundation for real-world AI, leveraging Sanro’s proprietary AI and interoperability framework to enable personalized research and care.”2

Together the acquisition of Toku and the investment from Sanro Health points tothe continued efforts of Topcon Healthcare to advance its “Healthcare for the Eye” strategy. This strategy has been described by the company as, “a connected care ecosystem that leverages AI-powered disease detection and management applied to noninvasive retinal imaging.”

As AI tools and platforms continue to evolve in the healthcare, and specifically ophthalmology field, Ophthalmology Times is committed to covering the latest advancements to empower providers to stay up to date and aware of the changing landscape.

References:
  1. Topcon Healthcare Signs Definitive Agreement to Acquire Toku Inc. Topcon Healthcare. News Release. October 17, 2025. Accessed October 28, 2025. https://eyewire.news/news/topcon-healthcare-signs-definitive-agreement-to-acquire-toku-inc
  2. Topcon Healthcare Invests in Sanro Health to Connect Clinical and Imaging Data for Smarter Care and Faster Discovery. Topcon Healthcare. News Release. October 23, 2025. Accessed October 28, 2025. https://topconhealthcare.com/article/topcon-healthcare-invests-in-sanro-health-to-connect-clinical-and-imaging-data-for-smarter-care-and-faster-discovery/

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.


Latest CME